BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Qalsody (Tofersen) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Qalsody (Tofersen)\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07294144-10800@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Qalsody (Tofersen): Phase 2 readout est. (NCT07294144)
DESCRIPTION:Qalsody (Tofersen)\, phase 2\, Amyotrophic Lateral Sclerosis.\n
 Study: Tofersen in Non-SOD1 ALS\nEstimated primary completion: January 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/tofersen#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07294144
URL:https://assetmemo.bio/drug/tofersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223723-10800@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20270526
DTEND;VALUE=DATE:20270527
SUMMARY:Qalsody (Tofersen): Phase 4 readout est. (NCT07223723)
DESCRIPTION:Qalsody (Tofersen)\, phase 4\, Amyotrophic Lateral Sclerosis.\n
 Study: A Study to Learn More About the Long-Term Safety of Tofersen (Qalso
 dy) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
 \nEstimated primary completion: 26 May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tofersen#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07223723
URL:https://assetmemo.bio/drug/tofersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04856982-10800@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20270807
DTEND;VALUE=DATE:20270808
SUMMARY:Qalsody (Tofersen): Phase 3 readout est. (NCT04856982)
DESCRIPTION:Qalsody (Tofersen)\, phase 3\, Amyotrophic Lateral Sclerosis.\n
 Study: Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and Abo
 ut Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Develop
 ed ALS Symptoms\nEstimated primary completion: 7 August 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tofersen#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04856982
URL:https://assetmemo.bio/drug/tofersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
